IRIDEX Co. (NASDAQ:IRIX) has received a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.

Brokerages have set a twelve-month consensus price objective of $13.00 for the company and are forecasting that the company will post ($0.21) EPS for the current quarter, according to Zacks. Zacks has also given IRIDEX an industry rank of 242 out of 265 based on the ratings given to related companies.

Several equities analysts have recently commented on IRIX shares. Zacks Investment Research upgraded IRIDEX from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. Roth Capital restated a “buy” rating and set a $13.00 price target on shares of IRIDEX in a research note on Friday, November 3rd.

In related news, CEO William M. Moore bought 5,000 shares of the business’s stock in a transaction on Tuesday, December 12th. The shares were bought at an average price of $7.84 per share, for a total transaction of $39,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.01% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in IRIDEX by 0.4% in the second quarter. Vanguard Group Inc. now owns 392,317 shares of the medical equipment provider’s stock valued at $3,880,000 after purchasing an additional 1,731 shares during the last quarter. Neuberger Berman Group LLC purchased a new position in IRIDEX in the third quarter valued at about $141,000. Lyon Street Capital LLC grew its stake in IRIDEX by 4.5% in the third quarter. Lyon Street Capital LLC now owns 442,647 shares of the medical equipment provider’s stock valued at $4,148,000 after purchasing an additional 19,059 shares during the last quarter. Susquehanna International Group LLP purchased a new position in IRIDEX in the second quarter valued at about $196,000. Finally, Ingalls & Snyder LLC purchased a new position in IRIDEX in the third quarter valued at about $234,000. Institutional investors own 49.31% of the company’s stock.

Shares of IRIDEX (NASDAQ:IRIX) traded down $0.20 during trading on Monday, hitting $7.95. The stock had a trading volume of 12,600 shares, compared to its average volume of 12,750. The stock has a market capitalization of $92.06, a price-to-earnings ratio of -4.65 and a beta of 1.31. IRIDEX has a 1 year low of $7.43 and a 1 year high of $16.37.

COPYRIGHT VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/01/08/zacks-brokerages-set-13-00-target-price-for-iridex-co-irix.html.

IRIDEX Company Profile

IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD).

Get a free copy of the Zacks research report on IRIDEX (IRIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.